Pandion Therapeutics to Present at Morgan Stanley Global Healthcare Conference

Rhea-AI Summary

Pandion Therapeutics, a clinical-stage biotechnology company focused on autoimmune diseases, has announced that CEO Rahul Kakkar will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020, at 2:00 p.m. ET. A live audio webcast will be available on Pandion's investor website, with a replay accessible for 90 days post-event. The company is advancing its TALON platform to develop immunomodulatory therapies, including its lead candidate PT101, currently in Phase 1a trials.

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a fireside chat at the upcoming Morgan Stanley 18^th Annual Global Healthcare Conference on Thursday, September 17^th, 2020 at 2:00 p.m. ET.

A live audio webcast of the fireside chat will be available on the Investors and News section of Pandion Therapeutics’ investor website at https://investors.pandiontx.com/. A replay of the webcast will be available for 90 days following the presentation.

About Pandion Therapeutics
Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells, is currently in a Phase 1a clinical trial. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit www.pandiontx.com.

For further information, please contact:

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
Sarah.mccabe@sternir.com

FAQ

When will Pandion Therapeutics' CEO speak at the Morgan Stanley Global Healthcare Conference?

Rahul Kakkar, CEO of Pandion Therapeutics, will speak at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020, at 2:00 p.m. ET.

Where can I watch the Pandion Therapeutics conference webcast?

The live audio webcast of the Pandion Therapeutics conference can be accessed on the company's investor website.

What is the focus of Pandion Therapeutics' research and development?

Pandion Therapeutics focuses on developing novel therapeutics to address unmet needs in autoimmune diseases.

What is PT101 and its current status?

PT101 is Pandion's lead product candidate, currently in Phase 1a clinical trials, designed to selectively expand regulatory T cells.